4basebio (LON:4BB) Stock Price Down 3.4% – Should You Sell?

4basebio PLC (LON:4BB) shares fell 3.4% on Thursday . The company traded as low as GBX 420 and last traded at GBX 420. 79 shares changed hands during trading, a decline of 95% from the average session volume of 1,599 shares. The stock had previously closed at GBX 435.

4basebio Stock Down 3.4%

The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The stock has a market capitalization of £65.04 million, a P/E ratio of -4.24 and a beta of 1.09. The stock’s fifty day simple moving average is GBX 501.30 and its two-hundred day simple moving average is GBX 590.56.

Insider Activity

In other news, insider Amy Walker purchased 2,650 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were purchased at an average price of GBX 586 per share, for a total transaction of £15,529. Company insiders own 12.07% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.